Avidity Biosciences Inc
NASDAQ Global MarketTotal Valuation
Avidity Biosciences Inc carries a market capitalization of 11.26B, placing it among publicly traded companies globally. Its enterprise value stands at -1.65B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 11.26B |
| Enterprise Value | -1.65B |
Share Statistics
Avidity Biosciences Inc currently has 151.21M shares outstanding.
| Shares Outstanding | 151.21M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Financial Position
Avidity Biosciences Inc maintains a current ratio of 9.20, meaning it holds 9.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 9.20 |
| Quick Ratio | 8.75 |
| Debt / Equity | 2.92 |
| Debt / EBITDA | -0.07 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -38.88 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Avidity Biosciences Inc's stock has gained approximately 0.30286344% over the past 52 weeks. The 50-day moving average sits at 72.52, while the 200-day moving average is 52.68.
| Beta (5Y) | N/A |
| 52-Week Price Change | 0.30286344% |
| 50-Day Moving Average | 72.52 |
| 200-Day Moving Average | 52.68 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Avidity Biosciences Inc generated 18.76M in revenue and converted that into -684.63M in net income, yielding earnings per share of -5.18. EBITDA reached -741.79M, while operating income came in at -745.94M.
| Revenue | 18.76M |
| Gross Profit | N/A |
| Operating Income | -745.94M |
| Pretax Income | -684.63M |
| Net Income | -684.63M |
| EBITDA | -741.79M |
| EBIT | -745.94M |
| Earnings Per Share (EPS) | -5.18 |
Balance Sheet
Avidity Biosciences Inc holds 1.70B in cash and equivalents against 49.25M in total debt, resulting in a net debt position of -382.52M. Total book value stands at -1.58B, with working capital of 1.60B providing operational flexibility.
| Cash & Cash Equivalents | 1.70B |
| Total Debt | 49.25M |
| Net Debt | -382.52M |
| Equity (Book Value) | -1.58B |
| Book Value Per Share | -11.93 |
| Working Capital | 1.60B |
Cash Flow
Avidity Biosciences Inc produced -650.44M in operating cash flow over the past twelve months. After subtracting -13.32M in capital expenditures, free cash flow totaled -663.76M - equivalent to -5.02 per share.
| Operating Cash Flow | -650.44M |
| Capital Expenditures | -13.32M |
| Free Cash Flow | -663.76M |
| FCF Per Share | -5.02 |
Margins
Avidity Biosciences Inc operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -3,977.30 and net profit margin of -3,650.39 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -3,977.30 |
| Pretax Margin | -3,650.39 |
| Profit Margin | -3,650.39 |
| EBITDA Margin | -3,955.17 |
Scores
Avidity Biosciences Inc posts an Altman Z-Score of -1.39, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -1.39 |